A Phase 1, Randomized, Open-Label, Parallel-Arm Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants
Latest Information Update: 23 Feb 2022
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Biogen
- 21 Feb 2022 Status changed from recruiting to completed.
- 07 Jan 2022 Status changed from not yet recruiting to recruiting.
- 16 Dec 2021 New trial record